

CDX2 (RM)

Concentrated and Prediluted Rabbit Monoclonal Antibody
901-3144-032619

BIOCARE
M E D I C A L

Catalog Number:	ACI 3144 A, B	API 3144 AA	VLTR 3144 G20
Description:	0.1, 0.5 mL, conc.	6.0 mL, RTU	20 mL, RTU
Dilution:	1:100	Ready-to-use	Ready-to-use
Diluent:	Da Vinci Green	N/A	N/A

Intended Use:

For In Vitro Diagnostic Use

CDX2 (RM) [EP25] is a rabbit monoclonal antibody that is intended for laboratory use in the qualitative identification of CDX2 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:

CDX2 is a homeobox gene that encodes an intestine-specific transcription factor (1). CDX2 has been useful to establish gastrointestinal origin of metastatic adenocarcinomas and carcinoids and can be especially useful in distinguishing metastatic colorectal adenocarcinoma from tumors of unknown origin (1-7). CDX2 has been shown to be more specific and more sensitive than villin or CK20 (1,4,6). CDX2 has also been shown to be expressed in mucinous ovarian cancer, bladder adenocarcinoma, cholangiocarcinoma and malignant germ cell tumors of the testes (1,2,6-8). Only very rare examples of carcinomas of the genitourinary and gynecologic tracts or breast, lung, and head and neck cancers showed elevated levels of CDX2 expression (1). Recently, a new rabbit monoclonal CDX2 has been developed and studies have shown that CDX2 rabbit monoclonal is a more sensitive clone than other CDX2 mouse monoclonal antibodies. Data has also shown that rabbit monoclonal CDX2 had fewer false negatives (9). The specificity was similar when compared to other mouse monoclonal CDX2 antibodies. However, in certain cancers, rabbit monoclonal CDX2 displayed a slightly higher percentage (9). The overall specificity for CDX2 antibodies can be significantly improved in a panel with CK7, TTF-1 and CDH17 (3,4,6,10).

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

Source: Rabbit monoclonal

Species Reactivity: Human; others not tested

Clone: EP25

Isotype: IgG

Protein Concentration: Call for lot specific Ig concentration.

Epitope/Antigen: A synthetic peptide corresponding to residues near the C-term of human CDX2 protein

Cellular Localization: Nuclear

Positive Tissue Control: Normal colon or colon cancer

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Protocol Recommendations (VALENT® Automated Slide Staining Platform):

VLTR3144 is intended for use with the VALENT. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Manager should be programmed as follows:

Deparaffinization: Deparaffinize for 8 minutes with Val DePar.

Pretreatment: Perform heat retrieval at 98°C for 60 minutes using Val AR-Lo pH, 5X (use at 1X).

Peroxidase Block: Block for 5 minutes with Val Peroxidase Block.

Protein Block (Optional): Incubate for 10-20 minutes with Val Background Block.

Primary Antibody: Incubate for 20 minutes.

Secondary: N/A

Linker: Incubate for 10 minutes with Val Universal Linker.

Polymer: Incubate for 20 minutes with Val Universal Polymer.

Chromogen: Incubate for 5 minutes with Val DAB.

Counterstain: Counterstain for 5 minutes with Val Hematoxylin.

Protocol Recommendations (intelliPATH FLX® and manual use):

Peroxide Block: Block for 5 minutes with Peroxidized 1.

Pretreatment: Perform heat retrieval using Diva Decloaker. Refer to the Diva Decloaker product data sheet for specific instructions.

Protein Block (Optional): Incubate for 5-10 minutes at RT with Background Punisher.

Primary Antibody: Incubate for 30 minutes at RT.

Probe: N/A

Polymer: Incubate for 30 minutes at RT with a secondary-conjugated polymer.

Chromogen: Incubate for 5 minutes at RT with Biocare's DAB – OR – Incubate for 5-7 minutes at RT with Warp Red.

Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

Protocol Recommendations (Ventana BenchMark ULTRA):

API3144 is compatible for use with the BenchMark ULTRA. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

Template/Detection: OptiView DAB IHC

Pretreatment Protocol: CC1 32 minutes

Peroxidase: Pre Primary Peroxidase Inhibitor

Primary Antibody: 16 minutes, 36°C

CDX2 (RM)

Concentrated and Prediluted Rabbit Monoclonal Antibody
901-3144-032619

BIOCARE
M E D I C A L

Limitations:

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (11)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (12)
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at <http://biocare.net>.

Troubleshooting:

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

References:

1. Werling RW, *et al.* CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. *Am J Surg Pathol.* 2003 Mar;27(3):303-10.
2. Moskaluk CA, *et al.* Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. *Mod Pathol.* 2003 Sep;16(9):913-9.
3. Kim JH, *et al.* Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. *Acta Cytol.* 2010 May-Jun;54(3):277-82.
4. Saad RS, *et al.* CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. *Appl Immunohistochem Mol Morphol.* 2009 May;17(3):196-201.
5. Qi W, *et al.* Characterization and applications of a newly developed rabbit monoclonal antibody to cytokeratin 7 (CK7) for immunohistochemistry. *Appl Immunohistochem Mol Morphol.* 2009 May;17(3):233-8.
6. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. *Diagn Pathol.* 2012 Jan 23;7:9.

References Cont'd:

7. Lee MJ, *et al.* CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules. *Tumour Biol.* 2012 Dec;33(6):2185-8.
8. Vang R, *et al.* Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. *Mod Pathol.* 2006 Nov;19(11):1421-8.
9. Borrisholt M, Nielsen S, Vyberg M. Demonstration of CDX2 is highly antibody dependent. *Appl Immunohistochem Mol Morphol.* 2013 Jan;21(1):64-72.
10. Panarelli NC, *et al.* Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. *Am J Clin Pathol.* 2012 Aug; 138(2):211-22.
11. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
12. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

VP Echelon Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare's antibodies by Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated, associated or related in any way. Ventana®, BenchMark®, *ultraView* and OptiView are trademarks of Roche.